Latest News

(UroToday.com)  Dr. Taplin began her discussion of the VISION trial by first reviewing the current therapeutic landscape of prostate cancer. While there are many life-prolonging options, unfortunately, the duration of response to these therapies in sequence is often short. The VISION trial was set up to evaluate the use of lutetium-PSMA in late-stage advanced prostate […]

(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic castration-resistant prostate cancer.

(UroToday.com) PARP inhibitors have shown promise in mCRPC patients with mutations in DNA repair, but ATM- and BRCA2-altered patients may respond differently to PARP inhibitors. Both rucaparib and olaparib were approved in May 2020 for BRCA2 and homologous recombination repair (HRR) gene-mutated mCRPC, respectively. However, the sequencing and efficacy of therapies in HRR-mutated mCRPC is not well-established. At the […]

(UroToday.com) We know from SEER data that black men are 1.7x more likely to be diagnosed with prostate cancer and are 2.1x more likely to die from their prostate cancer. This is not new data, as these trends were evident in the 1950s and 1970s as well but appear to be worsening in severity. This has […]

(UroToday.com) Radium-223 is an alpha particle emitter that causes DNA double strand breaks and has been FDA-approved for use in mCRPC patients with bone metastases. PARP-1 activity critically supports androgen receptor activity in mCRPC and potentiates androgen receptor-dependent DNA damage response pathways that promote prostate cancer cell survival. Niraparib is a potent and selective PARP-1/2 inhibitor […]

(UroToday.com) PARP inhibitors are approved for patients with metastatic prostate cancer and mutations in certain DNA-repair associated genes, such as ATM and BRCA2. ATM mutations have been included in a list of actionable mutations for PARP inhibitor therapeutic trials, however, despite preclinical evidence, PARP inhibitors have shown minimal clinical activity in ATM mutant prostate cancer. At […]

(UroToday.com) Curative intent therapy in muscle-invasive bladder cancer includes neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, whereas trimodality bladder preservation therapy (maximal TURBT followed by concurrent chemoradiation) is a standard treatment option for clinically localized muscle-invasive bladder cancer, also with curative intent. While no randomized trials exist, propensity risk-matched cohort analyses suggest similar DSS and OS […]

(UroToday.com) In the double-blind placebo-controlled ACIS study, investigator-assessed radiographic progression-free survival (rPFS) was significantly improved with apalutamide + abiraterone acetate + prednisone versus placebo + abiraterone acetate + prednisone in chemotherapy-naive mCRPC, with no significant new safety signals. Among prespecified subgroups, efficacy and safety were explored in two difficult to treat subgroups: patients with visceral disease […]

(UroToday.com) Men with advanced hormone-sensitive prostate cancer (HSPC) starting long-term androgen deprivation therapy (ADT) follow a highly variable clinical course. Treatment intensification with docetaxel or androgen receptor-targeted therapies improves outcomes but there is a risk of overtreatment, especially in non-metastatic (M0) or metastatic (M1) low volume disease. As such, Dr. Emily Grist and colleagues established a […]

(UroToday.com) Case 1: 65M with first PSA of 18 ng/mL. MRI of the prostate shows T3a lesion in the right peripheral zone, and biopsy reveals Gleason 4+4 adenocarcinoma. Conventional imaging is negative for metastatic disease, but a PSMA-PET shows oligometastatic disease. Specifically, he is found to have three small osseous metastatic lesions